{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:40Z","timestamp":1792801120461,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Providence\/Boston Center for AIDS Research","award":["P30AI042853"],"award-info":[{"award-number":["P30AI042853"]}],"id":[{"id":"https:\/\/ror.org\/05n52x113","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA043412"],"award-info":[{"award-number":["K01DA043412"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BU Peter Paul Career Development Professorship","id":[{"id":"https:\/\/ror.org\/02xjhr934","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12954-018-0263-5","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T08:17:07Z","timestamp":1542010627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs"],"prefix":"10.1186","volume":"15","author":[{"given":"K. B.","family":"Biello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Bazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Mimiaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Biancarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Edeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Salhaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Drainoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"issue":"5","key":"263_CR1","doi-asserted-by":"publisher","first-page":"e97596","DOI":"10.1371\/journal.pone.0097596","volume":"9","author":"A Lansky","year":"2014","unstructured":"Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9(5):e97596. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0097596\n                    \n                  .","journal-title":"PLoS One"},{"issue":"1","key":"263_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.15585\/mmwr.mm6701a5","volume":"67","author":"JC Burnett","year":"2018","unstructured":"Burnett JC, Broz D, Spiller MW, Wejnert C, Paz-Bailey G. HIV infection and HIV-associated behaviors among persons who inject drugs - 20 cities, United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(1):23\u20138. \n                    https:\/\/doi.org\/10.15585\/mmwr.mm6701a5\n                    \n                  .","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"263_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","volume":"25","author":"GJ MacArthur","year":"2014","unstructured":"MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34\u201352. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2013.07.001\n                    \n                  .","journal-title":"Int J Drug Policy"},{"key":"263_CR4","unstructured":"amfAR. Preventing HIV and hepatitis C among people who inject drugs: public funding for syringe services programs makes the difference; 2017. \n                    www.amfar.org\n                    \n                  . Accessed 26 Mar 2018."},{"issue":"16","key":"263_CR5","first-page":"443","volume":"64","author":"C Conrad","year":"2015","unstructured":"Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443\u20134 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25928470\n                    \n                  .","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"263_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1360-0443.2009.02759.x","volume":"105","author":"P Vickerman","year":"2010","unstructured":"Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction. 2010;105(2):311\u20138. \n                    https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02759.x\n                    \n                  .","journal-title":"Addiction"},{"key":"263_CR7","unstructured":"Centers for Disease Control and Prevention (CDC). Viral Hepatitis Surveillance United States, 2015 Surveillance for Viral Hepatitis \u2014 United States, 2015. \n                    https:\/\/www.cdc.gov\/hepatitis\/statistics\/2015surveillance\/pdfs\/2015hepsurveillancerpt.pdf\n                    \n                  . Accessed 26 Mar 2018."},{"issue":"47","key":"263_CR8","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.15585\/mmwr.mm6547e1","volume":"65","author":"C Wejnert","year":"2016","unstructured":"Wejnert C, Hess KL, Hall HI, et al. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs \u2014 United States. MMWR Morb Mortal Wkly Rep. 2016;65(47):1336\u201342. \n                    https:\/\/doi.org\/10.15585\/mmwr.mm6547e1\n                    \n                  .","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"263_CR9","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","volume":"71","author":"TJ Cicero","year":"2014","unstructured":"Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821\u20136. \n                    https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.366\n                    \n                  .","journal-title":"JAMA Psychiatry"},{"issue":"26","key":"263_CR10","first-page":"719","volume":"64","author":"CM Jones","year":"2015","unstructured":"Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719\u201325 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26158353\n                    \n                  .","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9719","key":"263_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(10)60232-2","volume":"375","author":"BM Mathers","year":"2010","unstructured":"Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014\u201328. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)60232-2\n                    \n                  .","journal-title":"Lancet"},{"key":"263_CR12","unstructured":"Preexposure Prophylaxis for the Prevention of HIV Infection in the United State \u2013 2017 Update Clinical Practice Guideline. \n                    https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2017.pdf\n                    \n                  . Accessed 11 Apr 2018."},{"issue":"9883","key":"263_CR13","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)61127-7\n                    \n                  .","journal-title":"Lancet"},{"issue":"7","key":"263_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/QAD.0000000000000613","volume":"29","author":"M Martin","year":"2015","unstructured":"Martin M, Vanichseni S, Suntharasamai P, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS. 2015;29(7):819\u201324. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000000613\n                    \n                  .","journal-title":"AIDS"},{"issue":"4","key":"263_CR15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/add.13759","volume":"112","author":"A Guise","year":"2017","unstructured":"Guise A, Albers ER, Strathdee SA. Pre-exposure prophylaxis (PrEP) for people who inject drugs: reconciling community views and biomedical advances. Addiction. 2017;112(4):584\u20135. \n                    https:\/\/doi.org\/10.1111\/add.13759\n                    \n                  .","journal-title":"Addiction"},{"issue":"1","key":"263_CR16","doi-asserted-by":"publisher","first-page":"e86584","DOI":"10.1371\/journal.pone.0086584","volume":"9","author":"SS Alistar","year":"2014","unstructured":"Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS One. 2014;9(1):e86584. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0086584\n                    \n                   Yazdanpanah Y, ed.","journal-title":"PLoS One"},{"issue":"5","key":"263_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAD.0000000000001747","volume":"32","author":"R Fu","year":"2018","unstructured":"Fu R, Owens DK, Brandeau ML. Cost-effectiveness of alternative strategies for provision of HIV pre-exposure prophylaxis for people who inject drugs. AIDS. 2018;32(5):1. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000001747\n                    \n                  .","journal-title":"AIDS"},{"issue":"1","key":"263_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M15-2634","volume":"165","author":"Cora L. Bernard","year":"2016","unstructured":"Bernard CL, Brandeau ML, Humphreys K, et al. Cost-effectiveness of HIV preexposure prophylaxis for people who inject drugs in the United States. Ann Intern Med. 2016. \n                    https:\/\/doi.org\/10.7326\/M15-2634\n                    \n                  .","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"263_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002312","volume":"14","author":"CL Bernard","year":"2017","unstructured":"Bernard CL, Owens DK, Goldhaber-Fiebert JD, Brandeau ML. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: a model-based analysis. PLoS Med. 2017;14(5):e1002312. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1002312\n                    \n                   Tsai AC, ed.","journal-title":"PLoS Med"},{"key":"263_CR20","doi-asserted-by":"publisher","first-page":"18899","DOI":"10.7448\/IAS.17.1.18899","volume":"17","author":"DJ Escudero","year":"2014","unstructured":"Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BD. HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc. 2014;17:18899. \n                    https:\/\/doi.org\/10.7448\/IAS.17.1.18899\n                    \n                  .","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"263_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","volume":"21","author":"FM Koechlin","year":"2017","unstructured":"Koechlin FM, Fonner VA, Dalglish SL, et al. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21(5):1325\u201335. \n                    https:\/\/doi.org\/10.1007\/s10461-016-1627-z\n                    \n                  .","journal-title":"AIDS Behav"},{"key":"263_CR22","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.1097\/QAI.0000000000001415","volume":"75 Suppl 3","author":"SM Walters","year":"2017","unstructured":"Walters SM, Rivera AV, Starbuck L, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011-2013. J Acquir Immune Defic Syndr. 2017;75 Suppl 3:S383\u201391. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000001415\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"263_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12954-017-0166-x","volume":"14","author":"SM Walters","year":"2017","unstructured":"Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40. \n                    https:\/\/doi.org\/10.1186\/s12954-017-0166-x\n                    \n                  .","journal-title":"Harm Reduct J"},{"issue":"9","key":"263_CR24","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s10461-014-0778-z","volume":"18","author":"M Stein","year":"2014","unstructured":"Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694\u2013700. \n                    https:\/\/doi.org\/10.1007\/s10461-014-0778-z\n                    \n                  .","journal-title":"AIDS Behav"},{"key":"263_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2016.02.044","volume":"164","author":"I Kuo","year":"2016","unstructured":"Kuo I, Olsen H, Patrick R, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8\u201313. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.02.044\n                    \n                  .","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"263_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jana.2017.04.005","volume":"28","author":"R Shrestha","year":"2017","unstructured":"Shrestha R, Karki P, Huedo-Medina TB, Copenhaver M. Intent to use preexposure prophylaxis (PrEP), HIV risk behaviors, and self-report neurocognitive symptoms by high-risk drug users: a mediation analysis. J Assoc Nurses AIDS Care. 2017;28(4):612\u201321. \n                    https:\/\/doi.org\/10.1016\/j.jana.2017.04.005\n                    \n                  .","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"8","key":"263_CR27","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1007\/s10461-018-2099-0","volume":"22","author":"Roman Shrestha","year":"2018","unstructured":"Shrestha R, Altice FL, Karki P, Copenhaver MM. Integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs: a pilot feasibility study. AIDS Behav. 2018. \n                    https:\/\/doi.org\/10.1007\/s10461-018-2099-0\n                    \n                  .","journal-title":"AIDS and Behavior"},{"issue":"1","key":"263_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1747-597X-10-1","volume":"10","author":"AY Spector","year":"2015","unstructured":"Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prev Policy. 2015;10(1):1. \n                    https:\/\/doi.org\/10.1186\/1747-597X-10-1\n                    \n                  .","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"11","key":"263_CR29","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1007\/s10461-018-2095-4","volume":"22","author":"Alex Dubov","year":"2018","unstructured":"Dubov A, Altice FL, Fraenkel L. An information\u2013motivation\u2013behavioral skills model of PrEP uptake. AIDS Behav. 2018. \n                    https:\/\/doi.org\/10.1007\/s10461-018-2095-4\n                    \n                  .","journal-title":"AIDS and Behavior"},{"key":"263_CR30","doi-asserted-by":"publisher","unstructured":"Bazzi AR, Biancarelli DL, Childs E, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDs. 2018. \n                    https:\/\/doi.org\/10.1089\/apc.2018.0126\n                    \n                  .","DOI":"10.1089\/apc.2018.0126"},{"key":"263_CR31","unstructured":"Clinical advisory: routine screening for hepatitis C. 2014. \n                    http:\/\/www.mass.gov\/eohhs\/docs\/dph\/aids\/hcv-clinical-advisory.pdf\n                    \n                  . Accessed 26 Mar 2018."},{"key":"263_CR32","unstructured":"MDPH Clinical advisory HIV transmission through injection drug use. 2017. \n                    https:\/\/hmccreg3.org\/wp-content\/uploads\/sites\/90\/2017\/12\/112707ClinicalAdvisory_HIV.pdf\n                    \n                  . Accessed 11 Apr 2018."},{"key":"263_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addbeh.2017.01.014","volume":"68","author":"A Macmadu","year":"2017","unstructured":"Macmadu A, Carroll JJ, Hadland SE, Green TC, Marshall BDL. Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically. Addict Behav. 2017;68:35\u20138. \n                    https:\/\/doi.org\/10.1016\/j.addbeh.2017.01.014\n                    \n                  .","journal-title":"Addict Behav"},{"key":"263_CR34","volume-title":"Selecting ethnographic informants","author":"JC Johnson","year":"1990","unstructured":"Johnson JC. Selecting ethnographic informants. Newbury Park: Sage Publications; 1990. \n                    http:\/\/www.loc.gov\/catdir\/enhancements\/fy0655\/90043951-d.html"},{"key":"263_CR35","volume-title":"Qualitative research and evaluation methods","author":"MQ Patton","year":"2002","unstructured":"Patton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks: Sage Publications; 2002. \n                    http:\/\/www.loc.gov\/catdir\/enhancements\/fy0658\/2001005181-d.html","edition":"3"},{"issue":"1","key":"263_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822x05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382. \n                    https:\/\/doi.org\/10.1177\/1525822x05279903\n                    \n                  .","journal-title":"Field Methods"},{"key":"263_CR37","volume-title":"InterViews: learning the craft of qualitative research interviewing","author":"S Kvale","year":"2009","unstructured":"Kvale S, Brinkman S. InterViews: learning the craft of qualitative research interviewing. 2nd ed. Los Angeles: SAGE PublicationsSage CA; 2009.","edition":"2"},{"issue":"2","key":"263_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/1525822x10388468","volume":"23","author":"JT DeCuir-Gunby","year":"2011","unstructured":"DeCuir-Gunby JT, Marshall PL, McCulloch AW. Developing and using a codebook for the analysis of interview data: an example from a professional development research project. Field Methods. 2011;23(2):136\u201355. \n                    https:\/\/doi.org\/10.1177\/1525822x10388468\n                    \n                  .","journal-title":"Field Methods"},{"issue":"2","key":"263_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1525822x980100020301","volume":"10","author":"KM MacQueen","year":"1998","unstructured":"MacQueen KM, McLellan E, Kay K, Milstein B. Codebook development for team-based qualitative analysis. Field Methods. 1998;10(2):31\u20136. \n                    https:\/\/doi.org\/10.1177\/1525822x980100020301\n                    \n                  .","journal-title":"Field Methods"},{"key":"263_CR40","volume-title":"Social foundations of thought and action: a social cognitive theory","author":"A Bandura","year":"1986","unstructured":"Bandura A. Social foundations of thought and action: a social cognitive theory. Englewood Cliffs: Prentice-Hall, Inc; 1986."},{"issue":"3","key":"263_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1037\/a0028208","volume":"80","author":"SA Safren","year":"2012","unstructured":"Safren SA, O\u2019Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404\u201315. \n                    https:\/\/doi.org\/10.1037\/a0028208\n                    \n                  .","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"263_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cbpra.2016.02.004","volume":"24","author":"SW Taylor","year":"2016","unstructured":"Taylor SW, Psaros C, Pantalone DW, et al. \u201cLife-Steps\u201d for PrEP adherence: demonstration of a CBT-based intervention to increase adherence to pre-exposure prophylaxis (PrEP) medication among sexual-minority men at high risk for HIV acquisition. Cogn Behav Pract. 2016;24(1):38\u201349. \n                    https:\/\/doi.org\/10.1016\/j.cbpra.2016.02.004\n                    \n                  .","journal-title":"Cogn Behav Pract"},{"issue":"Supplement 2","key":"263_CR43","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1097\/QAI.0b013e31815767d6","volume":"46","author":"JH Arnsten","year":"2007","unstructured":"Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. JAIDS J Acquir Immune Defic Syndr. 2007;46(Supplement 2):S64\u201371. \n                    https:\/\/doi.org\/10.1097\/QAI.0b013e31815767d6\n                    \n                  .","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"7","key":"263_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/apc.2009.0240","volume":"24","author":"AR Knowlton","year":"2010","unstructured":"Knowlton AR, Arnsten JH, Eldred LJ, et al. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors. AIDS Patient Care STDs. 2010;24(7):421\u20138. \n                    https:\/\/doi.org\/10.1089\/apc.2009.0240\n                    \n                  .","journal-title":"AIDS Patient Care STDs"},{"issue":"11","key":"263_CR45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/OLQ.0000000000000514","volume":"43","author":"PA Chan","year":"2016","unstructured":"Chan PA, Glynn TR, Oldenburg CE, et al. Implementation of preexposure prophylaxis for human immunodeficiency virus prevention among men who have sex with men at a New England sexually transmitted diseases clinic. Sex Transm Dis. 2016;43(11):717\u201323. \n                    https:\/\/doi.org\/10.1097\/OLQ.0000000000000514\n                    \n                  .","journal-title":"Sex Transm Dis"},{"issue":"5","key":"263_CR46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/QAI.0000000000001536","volume":"76","author":"R Plotzker","year":"2017","unstructured":"Plotzker R, Seekaew P, Jantarapakde J, et al. Importance of risk perception. JAIDS J Acquir Immune Defic Syndr. 2017;76(5):473\u201381. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000001536\n                    \n                  .","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"11","key":"263_CR47","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1080\/09540121.2016.1178703","volume":"28","author":"MA Kesler","year":"2016","unstructured":"Kesler MA, Kaul R, Myers T, et al. Perceived HIV risk, actual sexual HIV risk and willingness to take pre-exposure prophylaxis among men who have sex with men in Toronto, Canada. AIDS Care. 2016;28(11):1378\u201385. \n                    https:\/\/doi.org\/10.1080\/09540121.2016.1178703\n                    \n                  .","journal-title":"AIDS Care"},{"issue":"1","key":"263_CR48","doi-asserted-by":"publisher","first-page":"20777","DOI":"10.7448\/IAS.19.1.20777","volume":"19","author":"J Wilton","year":"2016","unstructured":"Wilton J, Kain T, Fowler S, et al. Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. J Int AIDS Soc. 2016;19(1):20777 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27265490\n                    \n                  . Accessed 5 Apr 2018.","journal-title":"J Int AIDS Soc"},{"key":"263_CR49","unstructured":"Miller WR, Rollnick S. Motivational interviewing: helping people change. Guilford Press; 2012."},{"issue":"4","key":"263_CR50","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S1077-7229(99)80052-2","volume":"6","author":"SA Safren","year":"1999","unstructured":"Safren SA, Otto MW, Worth JL. Life-steps: applying cognitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999;6(4):332\u201341. \n                    https:\/\/doi.org\/10.1016\/S1077-7229(99)80052-2\n                    \n                  .","journal-title":"Cogn Behav Pract"},{"issue":"3","key":"263_CR51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/apc.2017.0255","volume":"32","author":"JD Fuchs","year":"2018","unstructured":"Fuchs JD, Stojanovski K, Vittinghoff E, et al. A mobile health strategy to support adherence to antiretroviral preexposure prophylaxis. AIDS Patient Care STDs. 2018;32(3):104\u201311. \n                    https:\/\/doi.org\/10.1089\/apc.2017.0255\n                    \n                  .","journal-title":"AIDS Patient Care STDs"},{"issue":"3","key":"263_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/QAI.0000000000001828","volume":"79","author":"MA Spinelli","year":"2018","unstructured":"Spinelli MA, Scott HM, Vittinghoff E, et al. Brief report: a panel management and patient navigation intervention is associated with earlier PrEP initiation in a safety-net primary care health system. JAIDS J Acquir Immune Defic Syndr. 2018;79(3):347\u201351. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000001828\n                    \n                  .","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"10","key":"263_CR53","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.2105\/AJPH.2013.301491","volume":"103","author":"R de Vet","year":"2013","unstructured":"de Vet R, van Luijtelaar MJA, Brilleslijper-Kater SN, Vanderplasschen W, Beijersbergen MD, Wolf JRLM. Effectiveness of case management for homeless persons: a systematic review. Am J Public Health. 2013;103(10):e13\u201326. \n                    https:\/\/doi.org\/10.2105\/AJPH.2013.301491\n                    \n                  .","journal-title":"Am J Public Health"},{"issue":"2\u20133","key":"263_CR54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3109\/10826084.2011.522840","volume":"46","author":"CO Cunningham","year":"2011","unstructured":"Cunningham CO, Sohler NL, Cooperman NA, Berg KM, Litwin AH, Arnsten JH. Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users. Subst Use Misuse. 2011;46(2\u20133):218\u201332. \n                    https:\/\/doi.org\/10.3109\/10826084.2011.522840\n                    \n                  .","journal-title":"Subst Use Misuse"},{"issue":"4","key":"263_CR55","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s10461-016-1612-6","volume":"21","author":"EJ Edelman","year":"2017","unstructured":"Edelman EJ, Moore BA, Calabrese SK, et al. Primary care physicians\u2019 willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs. AIDS Behav. 2017;21(4):1025\u201333. \n                    https:\/\/doi.org\/10.1007\/s10461-016-1612-6\n                    \n                  .","journal-title":"AIDS Behav"},{"issue":"1","key":"263_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1360-0443.2011.03601.x","volume":"107","author":"JD Livingston","year":"2012","unstructured":"Livingston JD, Milne T, Fang ML, Amari E. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction. 2012;107(1):39\u201350. \n                    https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03601.x\n                    \n                  .","journal-title":"Addiction"},{"issue":"5","key":"263_CR57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11606-017-4289-2","volume":"33","author":"AP Goddu","year":"2018","unstructured":"Goddu AP, O\u2019Conor KJ, Lanzkron S, et al. Do words matter? Stigmatizing language and the transmission of bias in the medical record. J Gen Intern Med. 2018;33(5):685\u201391. \n                    https:\/\/doi.org\/10.1007\/s11606-017-4289-2\n                    \n                  .","journal-title":"J Gen Intern Med"},{"key":"263_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugpo.2009.10.010","volume":"21","author":"JF Kelly","year":"2010","unstructured":"Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21:202\u20137. \n                    https:\/\/doi.org\/10.1016\/j.drugpo.2009.10.010\n                    \n                  .","journal-title":"Int J Drug Policy"},{"issue":"4","key":"263_CR59","doi-asserted-by":"publisher","first-page":"ofy048","DOI":"10.1093\/ofid\/ofy048","volume":"5","author":"BJ Eckhardt","year":"2018","unstructured":"Eckhardt BJ, Scherer M, Winkelstein E, Marks K, Edlin BR. Hepatitis C treatment outcomes for people who inject drugs treated in an accessible care program located at a syringe service program. Open Forum Infect Dis. 2018;5(4):ofy048. \n                    https:\/\/doi.org\/10.1093\/ofid\/ofy048\n                    \n                  .","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"263_CR60","doi-asserted-by":"publisher","first-page":"e0194162","DOI":"10.1371\/journal.pone.0194162","volume":"13","author":"L Ti","year":"2018","unstructured":"Ti L, Soc\u00edas ME, Wood E, et al. The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PLoS One. 2018;13(3):e0194162. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0194162\n                    \n                  .","journal-title":"PLoS One"},{"issue":"1","key":"263_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41124-018-0035-6","volume":"3","author":"V Belackova","year":"2018","unstructured":"Belackova V, Salmon AM, Schatz E, Jauncey M. Drug consumption rooms (DCRs) as a setting to address hepatitis C \u2013 findings from an international online survey. Hepatol Med Policy. 2018;3(1):9. \n                    https:\/\/doi.org\/10.1186\/s41124-018-0035-6\n                    \n                  .","journal-title":"Hepatol Med Policy"},{"issue":"4","key":"263_CR62","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/add.13597","volume":"112","author":"BDL Marshall","year":"2017","unstructured":"Marshall BDL, Milloy M-J. Improving the effectiveness and delivery of pre-exposure prophylaxis (PrEP) to people who inject drugs. Addiction. 2017;112(4):580\u20132. \n                    https:\/\/doi.org\/10.1111\/add.13597\n                    \n                  .","journal-title":"Addiction"},{"issue":"2","key":"263_CR63","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.japh.2016.12.077","volume":"57","author":"TJ Stopka","year":"2017","unstructured":"Stopka TJ, Donahue A, Hutcheson M, Green TC. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc. 2017;57(2):S34\u201344. \n                    https:\/\/doi.org\/10.1016\/j.japh.2016.12.077\n                    \n                  .","journal-title":"J Am Pharm Assoc"},{"issue":"1","key":"263_CR64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1186\/1471-2334-13-565","volume":"13","author":"M-J Milloy","year":"2013","unstructured":"Milloy M-J, Kerr T, Salters K, et al. Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis. BMC Infect Dis. 2013;13(1):565. \n                    https:\/\/doi.org\/10.1186\/1471-2334-13-565\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"4","key":"263_CR65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","volume":"75","author":"TC Green","year":"2018","unstructured":"Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405. \n                    https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4614\n                    \n                  .","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"263_CR66","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/ADM.0000000000000381","volume":"12","author":"KE Moore","year":"2018","unstructured":"Moore KE, Oberleitner L, Smith KMZ, Maurer K, McKee SA. Feasibility and effectiveness of continuing methadone maintenance treatment during incarceration compared with forced withdrawal. J Addict Med. 2018;12(2):156\u201362. \n                    https:\/\/doi.org\/10.1097\/ADM.0000000000000381\n                    \n                  .","journal-title":"J Addict Med"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0263-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-018-0263-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0263-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:09:59Z","timestamp":1589526599000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-018-0263-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1186\/s12954-018-0263-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"2 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board of Boston University Medical Center approved all study protocols.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"55"}}